National Institute for Health and Care Excellence

Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.
National Institute for Health and Care Excellence

Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)

NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not ...
The National Institute for Health and Care Excellence

Focusing on what matters most to the NHS

The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...
National Institute for Health and Care Excellence

Guidance in topic selection

Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598] Medicine Awaiting decision 5 November 2025 Donanemab for reducing the risk of mild cognitive ...